BACKGROUND/AIM: Circulating cell-free DNA (cfDNA) isolated from serum by noninvasive procedures can serve as a potential biomarker for the early detection of many cancers. The aim of this study was to implement a simple, yet effective quantitative method for measuring the cfDNA in serum and to investigate the relationship between cfDNA and the occurrence of recurrence in breast cancer (BrCa) patients. PATIENTS AND METHODS: A total of 240 cases were selected, which comprised different subtypes of BrCa patients and control individuals. We selected 20 serum samples from patients which showed recurrence after 4-7 years of disease-free survival. SYBR green was used as a reporter molecule to estimate the amount of cfDNA in these serum samples. RESULTS: A global Wilcoxon analysis was performed to compare the cfDNA abundance between non-recurrent and recurrent patients. The amount of cfDNA was higher in recurrent patients (recurrent vs. non-recurrent ratio=1.3; p=0.03; AUC=0.76) compared to non-recurrent patients. The data between normal/healthy controls and non-recurrent patients indicated no significant differences (n=20 in each group, healthy to non-recurrent ratio=1.03; p=0.20; AUC=0.61). CONCLUSION: We implemented a straightforward one-step technique to measure the amount of cfDNA in serum, which can translate into a clinical diagnostic tool in the near future. The high levels of cfDNA in the serum of recurrent BrCa patients compared to non-recurrent BrCa patients indicates a possible uncovered role for circulating genetic information, which either contributes to the cancer recurrence phenomenon or at the very least, serves as an identifier for the potential of recurrence. Copyright 2022, International Institute of Anticancer Research.
BACKGROUND/AIM: Circulating cell-free DNA (cfDNA) isolated from serum by noninvasive procedures can serve as a potential biomarker for the early detection of many cancers. The aim of this study was to implement a simple, yet effective quantitative method for measuring the cfDNA in serum and to investigate the relationship between cfDNA and the occurrence of recurrence in breast cancer (BrCa) patients. PATIENTS AND METHODS: A total of 240 cases were selected, which comprised different subtypes of BrCa patients and control individuals. We selected 20 serum samples from patients which showed recurrence after 4-7 years of disease-free survival. SYBR green was used as a reporter molecule to estimate the amount of cfDNA in these serum samples. RESULTS: A global Wilcoxon analysis was performed to compare the cfDNA abundance between non-recurrent and recurrent patients. The amount of cfDNA was higher in recurrent patients (recurrent vs. non-recurrent ratio=1.3; p=0.03; AUC=0.76) compared to non-recurrent patients. The data between normal/healthy controls and non-recurrent patients indicated no significant differences (n=20 in each group, healthy to non-recurrent ratio=1.03; p=0.20; AUC=0.61). CONCLUSION: We implemented a straightforward one-step technique to measure the amount of cfDNA in serum, which can translate into a clinical diagnostic tool in the near future. The high levels of cfDNA in the serum of recurrent BrCa patients compared to non-recurrent BrCa patients indicates a possible uncovered role for circulating genetic information, which either contributes to the cancer recurrence phenomenon or at the very least, serves as an identifier for the potential of recurrence. Copyright 2022, International Institute of Anticancer Research.
Entities:
Keywords:
Circulating cell-free DNA (cfDNA); SYBR Green; breast cancer recurrence; fluorescence intensity; minimally non-invasive biomarker
Authors: Meera Srivastava; Ofer Eidelman; James Craig; Joshua Starr; Leonid Kvecher; Jianfang Liu; Matthew Hueman; Harvey B Pollard; Hai Hu; Craig D Shriver Journal: Mil Med Date: 2019-03-01 Impact factor: 1.437
Authors: Alessandro Leal; Nicole C T van Grieken; Doreen N Palsgrove; Jillian Phallen; Jamie E Medina; Carolyn Hruban; Mark A M Broeckaert; Valsamo Anagnostou; Vilmos Adleff; Daniel C Bruhm; Jenna V Canzoniero; Jacob Fiksel; Marianne Nordsmark; Fabienne A R M Warmerdam; Henk M W Verheul; Dick Johan van Spronsen; Laurens V Beerepoot; Maud M Geenen; Johanneke E A Portielje; Edwin P M Jansen; Johanna van Sandick; Elma Meershoek-Klein Kranenbarg; Hanneke W M van Laarhoven; Donald L van der Peet; Cornelis J H van de Velde; Marcel Verheij; Remond Fijneman; Robert B Scharpf; Gerrit A Meijer; Annemieke Cats; Victor E Velculescu Journal: Nat Commun Date: 2020-01-27 Impact factor: 14.919
Authors: Andjelija Zivanovic Bujak; Chen-Fang Weng; Maria João Silva; Miriam Yeung; Louisa Lo; Sarah Ftouni; Cassandra Litchfield; Yi-An Ko; Keilly Kuykhoven; Courtney Van Geelen; Sushma Chandrashekar; Mark A Dawson; Sherene Loi; Stephen Q Wong; Sarah-Jane Dawson Journal: PLoS Med Date: 2020-10-01 Impact factor: 11.069